Clinical trials: SCHIZOPHRENIA 1 (Disorder)
Schizophrenia
Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia
This is a multiple ascending dose study; the purpose of this study is to examine the safety, tolerability and pharmacokinetics (levels of drug in the blood) of SPD489 in Schizophrenic Patients who are currently maintained on a…
- Trial name
- NCT01457339
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Shire
Psychosis, SCHIZOPHRENIA 1 (Disorder)
Developing a Virtual Reality-assisted Intervention for Emotion Regulation Difficulties in Psychosis
Supporting people with psychosis to manage their emotions using virtual reality Many people who have experienced psychosis feel overwhelmed by their emotions. Emotions get in the way of doing what matters to them.
- Conditions
- Psychosis, SCHIZOPHRENIA 1 (Disorder), Schizophrenia and Related Disorders
- Trial name
- MANOEUVRE (NCT07623928)
- Testing
- MANOEUVRE therapy
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- King's College London
Schizophrenia
One Year Drug Treatment in First-Episode Schizophrenia
Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.
- Trial name
- NCT00159081
- Testing
- Haloperidol, Risperidone (drug)
- Where
- Germany
- Volunteers
- 159 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Schizophrenia, Psychotic Disorders
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
Cognitive enhancement is a primary goal in treating individuals with schizophrenia. Cognitive deficits are already present at the first break of the illness, seem to remain stable during early phases and noticeably influence…
- Trial name
- PAFIP2_nc1Y (NCT02534363)
- Testing
- Aripiprazole, Quetiapine, Ziprasidone
- Where
- Spain
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
SCHIZOPHRENIA 1 (Disorder), Nicotine Use
Behavioral Impact and Neural Correlates of Network-based Brain Stimulation in Schizophrenia
The primary aims of this study are to investigate the behavioral effects of applying targeted transcranial magnetic stimulation (TMS) to a node of the brain network subserving attention in schizophrenia and schizoaffective…
- Trial name
- NCT07190352
- Testing
- iTBS to the DMN, cTBS to the DMN
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia
A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 14 days of treatment with PF-05180999 in healthy subjects.
- Trial name
- NCT01429740
- Testing
- PF-05180999
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pfizer
Schizophrenia
Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral brexpipirazole in adolescent subjects with schizophrenia or Other Related Psychiatric Disorders.
- Trial name
- NCT02411695
- Testing
- Brexpiprazole (OPC-34712)
- Where
- 10 sites in United States
- Volunteers
- 43 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia Prodromal, SCHIZOPHRENIA 1 (Disorder)
Online Intervention To Improve Motivation
Participants will complete one online intervention lasting 12 weeks. Each week, they will be asked to complete a 20-30 minute session online.
- Conditions
- Schizophrenia Prodromal, SCHIZOPHRENIA 1 (Disorder), Psychosis
- Trial name
- Online Mot (NCT07157293)
- Testing
- Online Motivation Enhancing Intervention
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Alabama at Birmingham